This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 2 of 556

Strong Tumor Response Seen From Agios Pharma Cancer Metabolism Drug

By Adam Feuerstein

Patients with advanced blood cancer respond to treatment with Agios' AG-221, according to study results presented Sunday.

08:40AM 04/07/14


Biotech Selloff Causes Nasdaq to Drop Over 2%

By Adam Feuerstein

The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. The selling has gained in volume and speed as no one wants to be the last trader standing.

02:02PM 04/04/14


Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07:00AM 04/04/14


Tradable Biotech Stock Events for the Second Quarter

By Adam Feuerstein

The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.

09:00AM 04/03/14


Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study

By Adam Feuerstein

Northwest Bio is now acknowledging that no agreement with the FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.

08:30AM 04/03/14


Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa

By Adam Feuerstein

Tuesday's FDA panel voted overwhelmingly to support the approval of Mannkind's inhaled insulin Afrezza.

06:07AM 04/02/14


Mannkind Afrezza FDA Panel Live Blog

By Adam Feuerstein

TheStreet's biotech columnist Adam Feuerstein is providing live play-by-play of today's FDA advisory panel for Mannkind's inhaled insulin.

07:43AM 04/01/14


Mannkind: The Best Afrezza FDA Panel Preview Ever

By Adam Feuerstein

TheStreet's Adam Feuerstein sets the table for Mannkind and its inhaled, rapid-acting insulin Afrezza ahead of Tuesday's FDA advisory panel meeting.

07:56AM 03/31/14


Prana Alzheimer's Study Fails

By Adam Feuerstein

The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.

06:54AM 03/31/14


Northwest Bio, DCVax and 'Compassionate Use'

By Adam Feuerstein

Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.

11:33AM 03/29/14

Page 2 of 556

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs